Publication: Expression and hypermethylation of JAM and EPB41L3 in cervical squamous cell carcinoma: Clinical significance and applications
Authors
Gu, Yun ; Chu, Chengzhuo ; Yuan, Bei ; Wang, Jiandong ; Pan, Shiyang
item.page.secondaryauthor
item.page.director
Publisher
Universidad de Murcia. Departamento de BiologĂa Celular e HistologĂa
publication.page.editor
publication.page.department
DOI
https://doi.org/10.14670/HH-18-697
item.page.type
info:eu-repo/semantics/article
Description
Abstract
This study aimed to explore the expression
and hypermethylation of EPB41L3 and JAM3 in
cervical squamous cell carcinoma (CSCC) and to
investigate their clinical significance. JAM3 and
EPB41L3 mRNA expression was analyzed using a
public database, and protein expression was detected
using immunohistochemistry. The methylation status of
JAM3 and EPB41L3 was detected in CSCC tissues and
cervical cytological specimens using a quantitative
methylation-specific PCR (qMSP). JAM3 and EPB41L3
mRNA were downregulated in CSCC. The JAM3
protein was positively detected in 39.4% of CSCC
tissues and frequently expressed in those with lower
FIGO stage and no lymph node metastasis. EPB41L3
was expressed in 18.9% of CSCC tissues. The
hypermethylation of JAM3 was detected in 52.3% of
CSCC tissues and related to higher FIGO stage and
lymph node metastasis. EPB41L3 hypermethylation was
detected in 72.7% of CSCC tissues and related to older
ages and lymph node metastasis. In cervical cytological
specimens, no methylation of JAM3 and EPB41L3 was
found in normal or inflamed cervical epithelial cells. The
methylation of JAM3 was detected in 0%, 8.3%, and
6.3% of ASCUS, LSIL, and HSIL samples, while
EPB41L3 was detected in 12.5%, 42.9%, and 71.4%,
respectively. The sensitivity of the combination of JAM3
and EPB41L3 methylation detection in ASCUS, LSIL,
and HSIL was 8.3%, 15.6%, and 85.7%, respectively.
The specificity of the combination of JAM3 and
EPB41L3 methylation detection was 100%.
Downregulation of JAM3 and EPB41L3 by
hypermethylation was detected in CSCC. JAM3 and
EPB41L3 hypermethylation are potential biomarkers for
cervical cancer screening.
publication.page.subject
Citation
Histology and Histopathology, Vol.39, nÂş8, (2024)
ISSN.E.
ISSN.P.
item.page.embargo
Ir a EstadĂsticas
Este Ătem está sujeto a una licencia Creative Commons. http://creativecommons.org/licenses/by-nc-nd/4.0/